GSA Capital Partners LLP Buys 403 Shares of MoonLake Immunotherapeutics (NASDAQ:MLTX)

GSA Capital Partners LLP increased its position in MoonLake Immunotherapeutics (NASDAQ:MLTX) by 1.9% in the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 22,127 shares of the company’s stock after acquiring an additional 403 shares during the period. GSA Capital Partners LLP’s holdings in MoonLake Immunotherapeutics were worth $1,116,000 at the end of the most recent reporting period.

Several other hedge funds have also recently modified their holdings of MLTX. US Bancorp DE purchased a new stake in shares of MoonLake Immunotherapeutics during the third quarter valued at $44,000. Quarry LP boosted its holdings in shares of MoonLake Immunotherapeutics by 172.7% during the 2nd quarter. Quarry LP now owns 3,000 shares of the company’s stock valued at $132,000 after acquiring an additional 1,900 shares during the last quarter. Bellevue Group AG bought a new stake in shares of MoonLake Immunotherapeutics in the first quarter worth approximately $221,000. DNB Asset Management AS raised its holdings in shares of MoonLake Immunotherapeutics by 29.8% during the second quarter. DNB Asset Management AS now owns 7,372 shares of the company’s stock valued at $324,000 after purchasing an additional 1,694 shares during the last quarter. Finally, Handelsbanken Fonder AB lifted its position in MoonLake Immunotherapeutics by 26.2% during the third quarter. Handelsbanken Fonder AB now owns 13,000 shares of the company’s stock valued at $655,000 after purchasing an additional 2,700 shares during the period. Hedge funds and other institutional investors own 93.85% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have issued reports on MLTX shares. Cantor Fitzgerald restated an “overweight” rating on shares of MoonLake Immunotherapeutics in a research note on Monday, September 23rd. Wedbush restated an “outperform” rating and issued a $73.00 price objective (down from $92.00) on shares of MoonLake Immunotherapeutics in a research note on Tuesday, November 5th. Wolfe Research downgraded MoonLake Immunotherapeutics from an “outperform” rating to a “peer perform” rating in a research report on Monday, August 26th. HC Wainwright restated a “buy” rating and issued a $100.00 price target on shares of MoonLake Immunotherapeutics in a research report on Thursday. Finally, Needham & Company LLC reaffirmed a “buy” rating and set a $62.00 price objective on shares of MoonLake Immunotherapeutics in a research report on Thursday, September 12th. Two investment analysts have rated the stock with a hold rating, eight have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average target price of $78.80.

Insider Buying and Selling

In other news, Director Simon Sturge sold 171,000 shares of the business’s stock in a transaction on Friday, October 4th. The shares were sold at an average price of $53.72, for a total transaction of $9,186,120.00. Following the completion of the sale, the director now directly owns 171,980 shares of the company’s stock, valued at approximately $9,238,765.60. The trade was a 49.86 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 12.02% of the stock is currently owned by corporate insiders.

MoonLake Immunotherapeutics Stock Up 2.8 %

Shares of MoonLake Immunotherapeutics stock opened at $52.50 on Friday. The firm has a market cap of $3.35 billion, a price-to-earnings ratio of -40.70 and a beta of 1.28. MoonLake Immunotherapeutics has a twelve month low of $37.35 and a twelve month high of $64.98. The business has a 50-day moving average price of $49.68 and a 200-day moving average price of $45.62.

MoonLake Immunotherapeutics (NASDAQ:MLTX) last posted its quarterly earnings data on Thursday, November 7th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.12). During the same quarter last year, the company posted ($0.18) EPS. On average, equities analysts expect that MoonLake Immunotherapeutics will post -1.74 EPS for the current fiscal year.

MoonLake Immunotherapeutics Company Profile

MoonLake Immunotherapeutics, a clinical-stage biopharmaceutical company, engages in developing therapies. It develops Sonelokimab, a novel investigational Nanobody for the treatment of inflammation diseases; and hidradenitis suppurativa, psoriatic arthritis, axial spondyloarthritis, and psoriasis. MoonLake Immunotherapeutics was incorporated in 2020 and is headquartered in Zug, Switzerland.